Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Commissioned researcher Edison has published a detailed buy note on biotech mid-cap BTG (BTG) in which it tweaks its models upwards. The report asserts that BTG is both a beneficiary (Zytiga sales growth) and casualty (brachytherapy sales decline) of the changing treatment landscape for metastatic prostate cancer (mCRPC).
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Time left: 13:33:05